News & Events

Probiodrug AG has mandated ODDO SEYDLER BANK AG as Designated Sponsor

The shares are trading on XETRA, the electronic trading platform of Deutsche Börse.     HALLE (SAALE), Germany, 04 APRIL 2019 – Shares in Probiodrug AG, (Euronext […]

Probiodrug reports full year 2018 financial results

Conference call and webcast (in English) at 3:00 pm CET (10:00 am EDT) NIH grant of 15million USD received PQ912 Phase 2b core program prepared   HALLE (SAALE), […]

Probiodrug AG to Publish its Full Year 2018 Results on March 28, 2019

HALLE (SAALE), Germany, 21 March 2019 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), will publish […]

Probiodrug and Alzheimer’s Disease Cooperative Study (ADCS) Receive 15 Million USD National Institutes of Health (NIH) Grant for U.S. Phase 2b Core Program for PQ912

Study to Evaluate Safety and Efficacy of Drug Seeking to Treat Those with Mild Cognitive Impairment or Mild Dementia   HALLE (SAALE), Germany and San Diego, […]

Probiodrug to attend BIO Europe Spring in March 2019

HALLE (SAALE), Germany, 12 March 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to attend International Conferences in February 2019

HALLE (SAALE), Germany, 5 February 2019 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to attend at J.P. Morgan Healthcare Conference in January 2019

HALLE (SAALE), Germany, 18 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug to present at Antibody Engineering & Therapeutics in December 2018

HALLE (SAALE), Germany, 04 December 2018 – Probiodrug AG (“Probiodrug”, Euronext: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease, announces that […]

Probiodrug AG Reports Third Quarter 2018 Business Update

HALLE (SAALE), Germany, 29 November 2018 – Probiodrug AG (Euronext Amsterdam: PBD), a clinical stage biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD), today announces […]